Castle Biosciences
CSTL
67 hedge funds and large institutions have $176M invested in Castle Biosciences in 2019 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 28 increasing their positions, 12 reducing their positions, and 8 closing their positions.
188% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 8
133% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 12
99% more capital invested
Capital invested by funds: $88.1M → $176M (+$87.5M)
18% more funds holding
Funds holding: 57 → 67 (+10)
1.4% more ownership
Funds ownership: 28.52% → 29.93% (+1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.58M |
| 2 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$4.42M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$4.36M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$2.47M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAM
Nexpoint Asset Management
Dallas,
Texas
|
-$7.92M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$4.07M |
| 3 |
Millennium Management
New York
|
-$2.81M |
| 4 |
RI
RTW Investments
New York
|
-$2.79M |
| 5 |
PVI
Pura Vida Investments
New York
|
-$2.38M |
CSTL Hedge Fund Activity: Q4 2019 in Review
67 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q4 2019, worth a combined $176M — up 99% from $88.1M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CSTL positions and 8 closed out — a net gain of 15 holders — while 28 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $5.58M. The largest seller was Nexpoint Asset Management, cutting an estimated $7.92M.
- 67 institutional investors held Castle Biosciences (CSTL) as of Q4 2019, up from 57 in Q3 2019.
- Funds reported $176M of Castle Biosciences stock for Q4 2019, up 99% quarter-over-quarter.
- 23 funds opened new Castle Biosciences positions in Q4 2019 and 8 closed out, a net change of +15 holders.
- The largest Castle Biosciences buyer in Q4 2019 was BlackRock, an estimated $5.58M added.
- The largest Castle Biosciences seller in Q4 2019 was Nexpoint Asset Management, an estimated $7.92M sold.
Based on aggregated 13F filings for Q4 2019.